OBJECTIVE:Behavioral interventions for young adults show limited effects 1-year posttreatment. Few studies have examined the longitudinal outcomes of pharmacotherapy trials to reduce heavy drinking. This study examined the posttreatment, longitudinal effects of the first placebo-controlled trial of naltrexone in young adult heavy drinkers. METHOD: Randomized, double-blind, placebo-controlled, 8-week trial. Follow-up assessments at posttreatment (8 weeks [8W]), 3 months [3M], 6 months [6M], and 12 months [12M]). Participants were young adults ages 18-25 (N = 118) who reported ≥4 heavy drinking days in the prior 4 weeks. Outcomes were percent days heavy drinking (PHDD), percent days abstinent (PDA), and drinks per drinking day (DPDD). RESULTS: There were no time effects on PHDD. Treatment improvements were maintained posttreatment. A main effect of time was found for PDA. Both conditions continued to increase PDA posttreatment. For DPDD, a Treatment ×Time interaction emerged. In the naltrexone condition, DPDD increased from 8W to 6M and decreased from 6M to 12M, resulting in no net change posttreatment. The placebo group had a nonsignificant decrease in DPDD. The result was a significant benefit of naltrexone at 8W but not 12M. CONCLUSIONS: Participants showed improvements or no change on most outcomes over 1 year posttreatment. Naltrexone had significant benefits over placebo at 8W. Although differences among groups diminished during follow-up, overall effects were maintained. Behavioral monitoring during treatment may impact long-term outcomes more than a single intervention following discontinuation of active medication. (PsycINFO Database Record (c) 2016 APA, all rights reserved).
RCT Entities:
OBJECTIVE: Behavioral interventions for young adults show limited effects 1-year posttreatment. Few studies have examined the longitudinal outcomes of pharmacotherapy trials to reduce heavy drinking. This study examined the posttreatment, longitudinal effects of the first placebo-controlled trial of naltrexone in young adult heavy drinkers. METHOD: Randomized, double-blind, placebo-controlled, 8-week trial. Follow-up assessments at posttreatment (8 weeks [8W]), 3 months [3M], 6 months [6M], and 12 months [12M]). Participants were young adults ages 18-25 (N = 118) who reported ≥4 heavy drinking days in the prior 4 weeks. Outcomes were percent days heavy drinking (PHDD), percent days abstinent (PDA), and drinks per drinking day (DPDD). RESULTS: There were no time effects on PHDD. Treatment improvements were maintained posttreatment. A main effect of time was found for PDA. Both conditions continued to increase PDA posttreatment. For DPDD, a Treatment ×Time interaction emerged. In the naltrexone condition, DPDD increased from 8W to 6M and decreased from 6M to 12M, resulting in no net change posttreatment. The placebo group had a nonsignificant decrease in DPDD. The result was a significant benefit of naltrexone at 8W but not 12M. CONCLUSIONS:Participants showed improvements or no change on most outcomes over 1 year posttreatment. Naltrexone had significant benefits over placebo at 8W. Although differences among groups diminished during follow-up, overall effects were maintained. Behavioral monitoring during treatment may impact long-term outcomes more than a single intervention following discontinuation of active medication. (PsycINFO Database Record (c) 2016 APA, all rights reserved).
Authors: Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis Journal: J Clin Psychopharmacol Date: 2006-12 Impact factor: 3.153
Authors: Stephanie S O'Malley; William R Corbin; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; Jolomi Ikomi; Denise M Romano; Ran Wu; Benjamin A Toll; Kenneth J Sher; Ralitza Gueorguieva; Henry R Kranzler Journal: J Clin Psychiatry Date: 2015-02 Impact factor: 4.384
Authors: Lindsay M Squeglia; Matthew C Fadus; Erin A McClure; Rachel L Tomko; Kevin M Gray Journal: J Child Adolesc Psychopharmacol Date: 2019-04-22 Impact factor: 2.576
Authors: Krysten W Bold; Lisa M Fucito; Kelly S DeMartini; Robert F Leeman; Henry R Kranzler; William R Corbin; Stephanie S O'Malley Journal: Drug Alcohol Depend Date: 2016-11-03 Impact factor: 4.492
Authors: Matthew C Fadus; Lindsay M Squeglia; Emilio A Valadez; Rachel L Tomko; Brittany E Bryant; Kevin M Gray Journal: Curr Psychiatry Rep Date: 2019-09-14 Impact factor: 5.285
Authors: Corey R Roos; Krysten W Bold; Katie Witkiewitz; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; William R Corbin; Karl Mann; Henry R Kranzler; Stephanie S O'Malley Journal: Addiction Date: 2021-03-18 Impact factor: 7.256